# STAT6: Multidimensional analysis from hematopoietic immune regulation to pathogenesis mechanisms and therapeutic targets in hematologic malignancies

## TL;DR

This paper reviews the role of STAT6 in blood-related diseases and immune regulation, aiming to uncover new treatment strategies.

## Contribution

The paper systematically investigates STAT6's role in hematopoietic systems and hematologic malignancies, highlighting unique pathogenic mechanisms.

## Key findings

- STAT6 activation in hematologic malignancies is linked to a Th2-type immune microenvironment.
- Abnormal STAT6 activity may contribute to chemotherapy resistance in blood cancers.
- The study provides insights into STAT6's multifunctionality in immune regulation and disease progression.

## Abstract

Signal Transduction and Activation of Transcription 6 (STAT6) is a key molecule in the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signaling pathway. Primarily induced by Interleukin-4(IL-4) and Interleukin-13(IL-13), STAT6 undergoes phosphorylation and translocates to the nucleus, where it regulates gene transcription. While the abnormal activation and oncogenic functions of STAT6 in various solid tumors are well documented, its precise biological role in the hematopoietic system has not yet been systematically investigated. Compared with solid tumors, STAT6 activation in hematological malignancies occurs with the Type 2 T helper cell (Th2-type) immune microenvironment that it mediates, which is probably a unique pathogenic mechanism. This review, therefore, delves into the multifunctionality of STAT6 within the hematopoietic system (including viral infection and immune regulation) and hematologic malignancies, as well as its impact on chemotherapy resistance. The aim is to provide a theoretical basis for understanding the biological functions of STAT6 and developing new therapeutic approaches.